Literature DB >> 16725385

Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection.

R Losa1, M I Sierra, M O Gión, E Esteban, J M Buesa.   

Abstract

A reverse-phase HPLC method based on ion-pair formation with UV detection was set up for the simultaneous determination of gemcitabine diphosphate (dFdCDP) and triphosphate (dFdCTP) in human cells. The separation was achieved on a Tracer Excel ODSA column (100 mm x 4.6mm i.d., 3 microm particle size) at room temperature. Nine nucleotides were separated by isocratic elution in 26 min. Accuracy, linearity, sensitivity and precision studies for dFdCDP, dFdCTP, adenosine diphosphate (ADP) and triphosphate (ATP) validated this method. This assay was used to provide data from gemcitabine treated patients and in vitro grown human cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16725385     DOI: 10.1016/j.jchromb.2006.04.036

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  8 in total

1.  Development of Liposomal Gemcitabine with High Drug Loading Capacity.

Authors:  Hassan Tamam; Jinho Park; Hytham H Gadalla; Andrea R Masters; Jelan A Abdel-Aleem; Sayed I Abdelrahman; Aly A Abdelrahman; L Tiffany Lyle; Yoon Yeo
Journal:  Mol Pharm       Date:  2019-06-14       Impact factor: 4.939

2.  Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.

Authors:  Peter S Galatin; Ranjana H Advani; George A Fisher; Brian Francisco; Thomas Julian; Raquel Losa; Marta I Sierra; Branimir I Sikic
Journal:  Invest New Drugs       Date:  2010-03-28       Impact factor: 3.651

3.  Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.

Authors:  Carlos M Galmarini; Galya Warren; Ekta Kohli; Arin Zeman; Anton Mitin; Serguei V Vinogradov
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

4.  Radiosensitization by gemcitabine fixed-dose-rate infusion versus bolus injection in a pancreatic cancer model.

Authors:  Meredith Morgan; Mohamed A El Shaikh; Eyad Abu-Isa; Mary A Davis; Theodore S Lawrence
Journal:  Transl Oncol       Date:  2008-03       Impact factor: 4.243

5.  The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression.

Authors:  Saijie Zhu; Piyanuch Wonganan; Dharmika S P Lansakara-P; Hannah L O'Mary; Yue Li; Zhengrong Cui
Journal:  Biomaterials       Date:  2012-12-20       Impact factor: 12.479

6.  Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.

Authors:  Piyanuch Wonganan; Dharmika S P Lansakara-P; Saijie Zhu; Melisande Holzer; Michael A Sandoval; Mangalika Warthaka; Zhengrong Cui
Journal:  J Control Release       Date:  2013-04-06       Impact factor: 9.776

7.  Stability-indicating HPLC determination of gemcitabine in pharmaceutical formulations.

Authors:  Rahul Singh; Ashok K Shakya; Rajashri Naik; Naeem Shalan
Journal:  Int J Anal Chem       Date:  2015-03-08       Impact factor: 1.885

8.  Involvement of multidrug resistance protein 4 in the hepatocyte efflux of lamivudine and entecavir.

Authors:  Yu-Tian Liu; Wei Liu; Gang-Yan Zhu; Fu-Liang Wang; Qian Chen
Journal:  Mol Med Rep       Date:  2018-03-19       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.